0 134

Cited 0 times in

Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

DC Field Value Language
dc.date.accessioned2023-06-02T01:09:51Z-
dc.date.available2023-06-02T01:09:51Z-
dc.date.issued2022-04-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194699-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleReal-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorT.M. Kim-
dc.contributor.googleauthorS-H. Lee-
dc.contributor.googleauthorG-C. Chang-
dc.contributor.googleauthorJ-Y. Shih-
dc.contributor.googleauthorM.J. Hochmair-
dc.contributor.googleauthorJ.K. Sabari-
dc.contributor.googleauthorA.I. Spira-
dc.contributor.googleauthorC.A. Schioppa-
dc.contributor.googleauthorJ.B. Rose-
dc.contributor.googleauthorM. Chioda-
dc.contributor.googleauthorA. Panaccione-
dc.contributor.googleauthorP. Mahadevia-
dc.contributor.googleauthorB.C. Cho -
dc.identifier.doi10.1016/j.annonc.2022.02.044-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422001600-
dc.citation.volume33-
dc.citation.numbersuppl 2-
dc.citation.startPageS48-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(suppl 2) : S48, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.